Clinical Trials
2 trialsNCT02203513 2022-09-10
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03414047 2022-08-19
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed